Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mogamulizumab and TSEB in Stage IB-IIB Cutaneous T-Cell Lymphoma
NCT04128072Phase 2Recruiting
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Mar 2023
- Primary completion
- Oct 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 7
01
Overview
Phase 2, open-label, single-arm trial of mogamulizumab in mycosis fungoides (MF), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Progression Free Survival Rate at 48 weeks. Started Mar 2023; status: recruiting.
02
Drugs
mogamulizumab
03
Conditions
mycosis fungoides (MF)
Beyond the preview
Go deeper on NCT04128072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04128072.